1-3 of 3
W Frank Peacock, MD FACEP
Close
Sort by
Journal Articles

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Christine G Kohn, PharmD, Erin R Weeda, PharmD, W Frank Peacock, MD FACEP, Gregory J Fermann, MD, Christopher W. Baugh, MD MBA, Philip S Wells, MD FRCPC, MSc, Veronica Ashton, MPH, Concetta Crivera, PharmD, MPH, Peter Wildgoose, PhD, Jeff Schein, DrPH, MPH, Craig I Coleman, PharmD
Journal: Blood
Blood (2016) 128 (22): 2337.
https://doi.org/10.1182/blood.V128.22.2337.2337
Published: 2016
Journal Articles

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Concetta Crivera, Jeff Schein, W Frank Peacock, MD FACEP
Journal: Blood
Blood (2015) 126 (23): 747.
https://doi.org/10.1182/blood.V126.23.747.747
Published: 2015
Journal Articles

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Christine G Kohn, PharmD, Heather Rozjabek, MPH, Gregory J Fermann, MD, W Frank Peacock, MD FACEP, Concetta Crivera, Jeff Schein, Craig I Coleman, PharmD
Journal: Blood
Blood (2015) 126 (23): 2058.
https://doi.org/10.1182/blood.V126.23.2058.2058
Published: 2015